Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

The optimization of pyridazinone series of glucan synthase inhibitors.

Kuang R, Wu H, Ting PC, Aslanian RG, Cao J, Kim DW, Lee JF, Schwerdt J, Zhou G, Herr RJ, Zych AJ, Yang J, Lam SQ, Jenkins DM, Sakwa SA, Wainhaus S, Black TA, Cacciapuoti A, McNicholas PM, Xu Y, Walker SS.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5268-71. doi: 10.1016/j.bmcl.2012.06.091. Epub 2012 Jul 4.

PMID:
22818082
2.

Lead optimization of a sulfonylurea-based piperazine pyridazinone series of glucan synthase inhibitors.

Zych AJ, Lam SQ, Jenkins DM, Herr RJ, Ting PC, Lee JF, Kuang R, Wu H, Kim DW, Aslanian RG, Wainhaus S, Black TA, Cacciapuoti A, McNicholas PM, Xu Y, Walker SS.

Bioorg Med Chem Lett. 2012 Jul 15;22(14):4896-9. doi: 10.1016/j.bmcl.2012.04.127. Epub 2012 May 17.

PMID:
22687744
3.

Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors.

Walker SS, Xu Y, Triantafyllou I, Waldman MF, Mendrick C, Brown N, Mann P, Chau A, Patel R, Bauman N, Norris C, Antonacci B, Gurnani M, Cacciapuoti A, McNicholas PM, Wainhaus S, Herr RJ, Kuang R, Aslanian RG, Ting PC, Black TA.

Antimicrob Agents Chemother. 2011 Nov;55(11):5099-106. doi: 10.1128/AAC.00432-11. Epub 2011 Aug 15.

4.

SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors.

Zhou G, Ting PC, Aslanian R, Cao J, Kim DW, Kuang R, Lee JF, Schwerdt J, Wu H, Herr RJ, Zych AJ, Yang J, Lam S, Wainhaus S, Black TA, McNicholas PM, Xu Y, Walker SS.

Bioorg Med Chem Lett. 2011 May 15;21(10):2890-3. doi: 10.1016/j.bmcl.2011.03.083. Epub 2011 Mar 30.

PMID:
21489787
5.

The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors.

Ting PC, Kuang R, Wu H, Aslanian RG, Cao J, Kim DW, Lee JF, Schwerdt J, Zhou G, Wainhaus S, Black TA, Cacciapuoti A, McNicholas PM, Xu Y, Walker SS.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1819-22. doi: 10.1016/j.bmcl.2011.01.058. Epub 2011 Jan 21.

PMID:
21316223
6.

Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).

McNicholas PM, Mann PA, Wojcik L, Qiu P, Lee E, McCarthy M, Shen J, Black TA, Strizki JM.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):222-9. doi: 10.1097/QAI.0b013e3181ff63ee.

PMID:
21209592
7.

Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.

Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, Cornely OA, Patino H, Black TA.

Antimicrob Agents Chemother. 2009 Dec;53(12):5026-34. doi: 10.1128/AAC.01031-09. Epub 2009 Sep 28.

8.

Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species.

Sóczó G, Kardos G, McNicholas PM, Balogh E, Gergely L, Varga I, Kelentey B, Majoros L.

J Antimicrob Chemother. 2007 Nov;60(5):1004-9. Epub 2007 Sep 17.

PMID:
17875607
9.

Posaconazole susceptibility testing against Candida species: comparison of broth microdilution and E-test methods.

Sóczó G, Kardos G, McNicholas PM, Falusi E, Gergely L, Majoros L.

Mycoses. 2007 May;50(3):178-82.

PMID:
17472612
10.

Clinical evaluation of the Sensititre YeastOne plate for testing susceptibility of filamentous fungi to posaconazole.

Patel R, Mendrick C, Knapp CC, Grist R, McNicholas PM.

J Clin Microbiol. 2007 Jun;45(6):2000-1. Epub 2007 Apr 11.

11.

Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.

Chau AS, Chen G, McNicholas PM, Mann PA.

Antimicrob Agents Chemother. 2006 Nov;50(11):3917-9. Epub 2006 Sep 11.

12.

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.

Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15.

13.

Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole.

Wheat LJ, Connolly P, Smedema M, Durkin M, Brizendine E, Mann P, Patel R, McNicholas PM, Goldman M.

J Antimicrob Chemother. 2006 Jun;57(6):1235-9. Epub 2006 Apr 20.

PMID:
16627592
14.

Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans.

Chau AS, Gurnani M, Hawkinson R, Laverdiere M, Cacciapuoti A, McNicholas PM.

Antimicrob Agents Chemother. 2005 Sep;49(9):3646-51.

15.

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Munayyer HK, Mann PA, Chau AS, Yarosh-Tomaine T, Greene JR, Hare RS, Heimark L, Palermo RE, Loebenberg D, McNicholas PM.

Antimicrob Agents Chemother. 2004 Oct;48(10):3690-6.

16.

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM.

Antimicrob Agents Chemother. 2004 Jun;48(6):2124-31.

17.
18.

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.

Li X, Brown N, Chau AS, López-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM.

J Antimicrob Chemother. 2004 Jan;53(1):74-80. Epub 2003 Dec 4.

PMID:
14657086
19.

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, Loebenberg D, DiDomenico B, Hare RS, Walker SS, McNicholas PM.

Antimicrob Agents Chemother. 2003 Feb;47(2):577-81.

20.

Incidence of high-level evernimicin resistance in Enterococcus faecium among food animals and humans.

Aarestrup FM, McNicholas PM.

Antimicrob Agents Chemother. 2002 Sep;46(9):3088-90.

22.

EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance.

Mann PA, Xiong L, Mankin AS, Chau AS, Mendrick CA, Najarian DJ, Cramer CA, Loebenberg D, Coates E, Murgolo NJ, Aarestrup FM, Goering RV, Black TA, Hare RS, McNicholas PM.

Mol Microbiol. 2001 Sep;41(6):1349-56.

23.

A novel site of antibiotic action in the ribosome: interaction of evernimicin with the large ribosomal subunit.

Belova L, Tenson T, Xiong L, McNicholas PM, Mankin AS.

Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3726-31. Epub 2001 Mar 20.

24.

Effects of mutations in ribosomal protein L16 on susceptibility and accumulation of evernimicin.

McNicholas PM, Mann PA, Najarian DJ, Miesel L, Hare RS, Black TA.

Antimicrob Agents Chemother. 2001 Jan;45(1):79-83.

25.

Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both gram-positive and gram-negative bacteria.

McNicholas PM, Najarian DJ, Mann PA, Hesk D, Hare RS, Shaw KJ, Black TA.

Antimicrob Agents Chemother. 2000 May;44(5):1121-6.

26.

Functional dissection of the molybdate-responsive transcription regulator, ModE, from Escherichia coli.

McNicholas PM, Mazzotta MM, Rech SA, Gunsalus RP.

J Bacteriol. 1998 Sep;180(17):4638-43.

27.

Anaerobic regulation of the Escherichia coli dmsABC operon requires the molybdate-responsive regulator ModE.

McNicholas PM, Chiang RC, Gunsalus RP.

Mol Microbiol. 1998 Jan;27(1):197-208.

28.
29.

Expression of the heme biosynthetic pathway genes hemCD, hemH, hemM, and hemA of Escherichia coli.

McNicholas PM, Javor G, Darie S, Gunsalus RP.

FEMS Microbiol Lett. 1997 Jan 1;146(1):143-8.

30.

The Escherichia coli modE gene: effect of modE mutations on molybdate dependent modA expression.

McNicholas PM, Chiang RC, Gunsalus RP.

FEMS Microbiol Lett. 1996 Nov 15;145(1):117-23.

PMID:
8931336

Supplemental Content

Loading ...
Support Center